Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000684997 | SCV000812465 | likely benign | Rhabdoid tumor predisposition syndrome 2 | 2024-06-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001021984 | SCV001183670 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-26 | criteria provided, single submitter | clinical testing | The c.4171-5T>C intronic variant results from a T to C substitution 5 nucleotides upstream from coding exon 29 in the SMARCA4 gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
ARUP Laboratories, |
RCV001811439 | SCV001477774 | uncertain significance | not provided | 2020-01-31 | criteria provided, single submitter | clinical testing | The SMARCA4 c.4171-5T>C variant (rs1157173095), to our knowledge, is not reported in the medical literature but is reported in the ClinVar database (Variation ID: 565433). This variant is only observed on 2 alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. This is an intronic variant in a weakly conserved nucleotide, but computational analyses (Alamut v.2.11) predict that this variant may impact splicing by weakening the nearby canonical acceptor splice site. However, given the lack of clinical and functional data, the significance of this variant is uncertain at this time. |
Sema4, |
RCV001021984 | SCV002532948 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-02-04 | criteria provided, single submitter | curation |